Viridian Therapeutics Inc. has released a corporate presentation detailing its current initiatives and advancements in therapeutic development. The company is focusing on identifying market opportunities with unmet needs and advancing next-generation strategies. Key developments include the Thyroid Eye Disease (anti-IGF-1R) portfolio, featuring Veligrotug, which has reported positive topline data and is planning a Biologics License Application in the second half of 2025. Pivotal trials are ongoing for VRDN-003, with potential subcutaneous delivery. The FcRn-Targeting Autoimmune Portfolio, including VRDN-006 and VRDN-008, is progressing with Phase 1 trials and an expected IND submission by year-end 2025. Financially, Viridian reports $637 million in cash as of March 31, 2025, with a runway into the second half of 2027. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.